Bone Therapeutics strengthens leadership with new CMO
Bone Therapeutics, a bone cell therapy company focusing on orthopaedics and bone disease, has appointed Miguel Forte to the position of Chief Medical Officer (CMO). Forte arrives at the company with an impressive CV, having worked across a wide range of companies in his twenty years of experience in the life sciences industry.
Forte began his career as Medical Director for Abbott Laboratories before moving onto work within the EMA. He has been Associate Professor with the Universidade de Aveiro for the last six years and leaves his role at TxCell, as COO and CMO to join his new company.
The varied experience that Forte carries into the role was recognised by Bone Therapeutics in its announcement of his appointment, stressing his ‘broad expertise’. His key responsibilities will be to develop the company’s clinical development strategy and to shepherd through to markets its product pipeline. It was also noted that he would also be instrumental in increasing the visibility of the company in the medical community.
Regarding the move to his new role, Forte said: “I am very excited to be joining Bone Therapeutics, a leading biotechnology company in bone cell therapy products. The Company has an advanced clinical pipeline with promising products in clinical development and I am impressed with its progress to date. I look forward to working with the Bone Therapeutics team to realise the potential of its ground breaking products for the benefits of patients.”
Thomas Lienard, Chief Executive Officer of the company, added: “We are delighted to strengthen our clinical development team with the appointment of Dr Forte. His vast expertise in cell therapy will be a strong asset to our company and will further drive the progress of Bone Therapeutics’ innovative pipeline. In addition to his specific experience with cell therapy products, Dr Forte has extensive experience in interacting with regulatory bodies and establishing strong relationships with investigators and key opinion leaders.”